Compounds > emd 53998
Page last updated: 2024-09-05

emd 53998 and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide

emd 53998 has been researched along with n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide in 1 studies

Compound Research Comparison

Studies
(emd 53998)		Trials
(emd 53998)		Recent Studies (post-2010)
(emd 53998)		Studies
(n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide)		Trials
(n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide)		Recent Studies (post-2010) (n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide)
112092455

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borbély, A; Edes, I; Papp, Z; Stienen, GJ; Van Der Velden, J1

Other Studies

1 other study(ies) available for emd 53998 and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide

ArticleYear
Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.
    Journal of muscle research and cell motility, 2004, Volume: 25, Issue:3

    Topics: Acetamides; Adult; Aged; Calcium; Cell Membrane Permeability; Female; Heart Failure; Humans; In Vitro Techniques; Male; Middle Aged; Myocardium; Myocytes, Cardiac; Pyridazines; Quinolines; Thiadiazines; Tissue Donors

2004